ALGN Stock Analysis: Align Technology | NASDAQ

Medical Instruments & Supplies | NASDAQ, USA | Market Cap: 11.864m USD | 12M Return: 19.5% | US0162551016 | Charts, Fundamentals & Technical Analysis

Clear Aligners, Retainers, Intraoral Scanners, Dental Software
Total Rating 54
Safety 84
Buy Signal -0.63
Health Care Supplies
Sub-Industry Rotation: +4.5
Market Cap: 11.9B
Avg Turnover: 178M
Risk 3d forecast
Volatility40.6%
VaR 5th Pctl6.76%
VaR vs Median1.00%
Reward TTM
Sharpe Ratio0.54
Rel. Str. IBD52.1
Rel. Str. Peer Group38.6 pctl
Character TTM
Beta0.931
Beta Downside0.991
Hurst Exponent0.462
Choppyness54.4%
Drawdowns 3y
Max DD62.19%
CAGR/Max DD-0.16
CAGR/Mean DD-0.27
EPS (Earnings per Share) EPS (Earnings per Share) of ALGN over the last years for every Quarter: "2021-09": 2.87, "2021-12": 2.83, "2022-03": 2.13, "2022-06": 2, "2022-09": 1.36, "2022-12": 1.73, "2023-03": 1.82, "2023-06": 2.22, "2023-09": 2.14, "2023-12": 2.42, "2024-03": 2.14, "2024-06": 2.41, "2024-09": 2.35, "2024-12": 2.44, "2025-03": 2.13, "2025-06": 2.49, "2025-09": 2.61, "2025-12": 3.29, "2026-03": 2.58, "2026-06": 2.05, "2026-09": 2.37,
EPS CAGR: 7.97%
EPS Trend: 91.8%
Last SUE: 0.33
Qual. Beats: 0
Revenue Revenue of ALGN over the last years for every Quarter: 2021-09: 1015.906, 2021-12: 1031.099, 2022-03: 973.219, 2022-06: 969.553, 2022-09: 890.348, 2022-12: 901.515, 2023-03: 943.147, 2023-06: 1002.173, 2023-09: 960.214, 2023-12: 956.726, 2024-03: 997.431, 2024-06: 1028.49, 2024-09: 977.872, 2024-12: 995.219, 2025-03: 979.262, 2025-06: 1012.449, 2025-09: 995.692, 2025-12: 1047.560999, 2026-03: 1040.087, 2026-06: 1056.192, 2026-09: 1014.763,
Rev. CAGR: 2.34%
Rev. Trend: 94.0%
Last SUE: 0.57
Qual. Beats: 0

Warnings

Below Avwap Earnings
Below Sma 200d

Tailwinds

No distinct edge detected

Seasonality 11.9 years of data, until 10/2026

Jan +0.8% 0
Feb +5.2% 4
Mar -6.4% 4
Apr +2.8% 4
May -0.3% 4
Jun -0.4% 4
Jul -0.1% 0
Aug -3.4% 4
Sep -2.7% 47
Oct -1.6% 0
Nov +2.1% 64
Dec +0.9% 0

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.

Description: ALGN Align Technology

Align Technology, Inc. (NASDAQ: ALGN) is a global medical device company that designs, manufactures, and markets the Invisalign system of clear aligners, Vivera retainers, and iTero intraoral scanners and related services. The company operates through two main segments: Clear Aligner and Imaging Systems and CAD/CAM Services. The Clear Aligner segment offers a wide range of Invisalign products targeting adults, teens, and younger patients (ages 6-10) with mixed dentition, including various treatment tiers (Express, Lite, Moderate, Go), retention products, training tools, the Invisalign Professional Whitening system, and the Invisalign Palatal Expander, a 3D printed orthodontic device. The Imaging Systems and CAD/CAM Services segment provides the iTero intraoral scanner, exocad design software, orthodontic and restorative software, and various digital tools such as the Invisalign Outcome Simulator, Progress Assessment tool, Oral Health Suite, and iTero TimeLapse technology, supported by subscription software, disposables, scanner rentals, and pay-per-scan services.

Founded in 1997 and headquartered in Tempe, Arizona, Align Technology is classified within the Health Care sector, specifically the Health Care Supplies sub-industry, and has a mid-cap market capitalization of approximately $9.94 billion. The company operates in the United States, Switzerland, and internationally, and was IPOd on January 26, 2001. Align Technologys business model is heavily focused on orthodontics and digital dentistry, leveraging proprietary 3D printing and scanning technologies to serve dental professionals, orthodontists, and patients globally. As a key player in the clear aligner market, Align Technology competes in a growing segment of the dental industry, which is increasingly shifting toward digital workflows and minimally invasive cosmetic dental solutions.

Headlines to Watch Out For
  • Invisalign teen and Phase I expansion drives adolescent case volume
  • iTero scanner adoption and subscription software recurring revenue
  • Consumer discretionary dental spending weakness pressures clear aligner ASPs
  • Chinese growth and APAC expansion offset mature US market saturation
  • Class action litigation and regulatory scrutiny over clear aligner marketing practices
  • Capital allocation through share buybacks and margin discipline from cost optimization
Piotroski VR-10 (Strict) 5.5
Net Income: 491.9m TTM > 0 and > 6% of Revenue
FCF/TA: 0.09 > 0.02 and ΔFCF/TA 0.15 > 1.0
NWC/Revenue: 19.54% < 20% (prev 14.25%; Δ 5.29% < -1%)
CFO/TA 0.12 > 3% & CFO 749.9m > Net Income 491.9m
Net Debt (-998.5m) to EBITDA (903.7m): -1.10 < 3
Current Ratio: 1.42 > 1.5 & < 3
Outstanding Shares: last quarter (71.0m) vs 12m ago -1.94% < -2%
Gross Margin: 67.58% > 18% (prev 68.41%; Δ -0.83% > 0.5%)
Asset Turnover: 65.21% > 50% (prev 63.89%; Δ 1.32% > 0%)
Interest Coverage Ratio: 31.16 > 6 (EBIT TTM 665.6m / Interest Expense TTM 21.4m)
Altman Z'' 4.88
A: 0.12 (Total Current Assets 2.73b - Total Current Liabilities 1.91b) / Total Assets 6.52b
B: 0.40 (Retained Earnings 2.64b / Total Assets 6.52b)
C: 0.10 (EBIT TTM 665.6m / Avg Total Assets 6.38b)
D: 1.94 (Book Value of Equity 4.31b / Total Liabilities 2.22b)
Altman-Z'' = 4.88 = AA
Beneish M -3.00
DSRI: 0.98 (Receivables 1.16b/1.14b, Revenue 4.16b/3.98b)
GMI: 1.01 (GM 68.41% / 67.58%)
AQI: 1.00 (AQ_t 0.39 / AQ_t-1 0.38)
SGI: 1.04 (Revenue 4.16b / 3.98b)
TATA: -0.04 (NI 491.9m - CFO 749.9m) / TA 6.52b)
Beneish M = -3.00 (Cap -4..+1) = AA
What is the price of ALGN shares?

As of November 20, 2026, the stock is trading at USD 159.68 with a total of 1,199,090 shares traded. Over the past week, the price has changed by -4.37%, over one month by +7.17%, over three months by -2.06% and over the past year by +19.45%.

Current recommended Stop Loss: 147.60 (which is 7.6% or 2.1 ATR below the current price).

Is ALGN a buy, sell or hold?

Align Technology has received a consensus analysts rating of 3.69. Therefore, it is recommended to hold ALGN.

  • StrongBuy: 5
  • Buy: 2
  • Hold: 8
  • Sell: 1
  • StrongSell: 0

What are the forecasts/targets for the ALGN price?
Analysts Target Price 185.8 16.4%
Align Technology (ALGN) - Fundamental Data Overview as of 17 November 2026
Market Cap USD = 11.9b (11.9b USD * 1.0 USD.USD)
P/E Trailing = 24.5364
P/E Forward = 13.6799
P/S = 2.853
P/B = 2.7556
P/EG = 0.7731
Revenue TTM = 4.16b USD
EBIT TTM = 665.6m USD
EBITDA TTM = 903.7m USD
Long Term Debt = 112.3m USD (estimated: total debt 146.5m - short term 34.2m)
Short Term Debt = 34.2m USD (from shortTermDebt, last quarter)
Debt = 146.5m USD (from shortLongTermDebtTotal, last quarter) (leases 146.5m already included)
Net Debt = -998.5m USD (calculated: Debt 146.5m - CCE 1.14b)
Enterprise Value = 10.9b USD (11.9b + Debt 146.5m - CCE 1.14b)
Interest Coverage Ratio = 31.16 (Ebit TTM 665.6m / Interest Expense TTM 21.4m)
EV/FCF = 18.03x (Enterprise Value 10.9b / FCF TTM 602.5m)
FCF Yield = 5.54% (FCF TTM 602.5m / Enterprise Value 10.9b)
FCF Margin = 14.49% (FCF TTM 602.5m / Revenue TTM 4.16b)
Net Margin = 11.83% (Net Income TTM 491.9m / Revenue TTM 4.16b)
Gross Margin = 67.58% ((Revenue TTM 4.16b - Cost of Revenue TTM 1.35b) / Revenue TTM)
Gross Margin QoQ = 68.73% (prev 65.14%)
Tobins Q-Ratio = 1.67 (Enterprise Value 10.9b / Total Assets 6.52b)
Interest Expense / Debt = 14.58% (Interest Expense 21.4m / Debt 146.5m)
Taxrate = 23.65% (152.4m / 644.2m)
NOPAT = 508.2m (EBIT 665.6m * (1 - 23.65%))
Current Ratio = 1.42 (Total Current Assets 2.73b / Total Current Liabilities 1.91b)
Debt / Equity = 0.03 (Debt 146.5m / totalStockholderEquity, last quarter 4.31b)
Debt / EBITDA = -1.10 (Net Debt -998.5m / EBITDA 903.7m)
Debt / FCF = -1.66 (Net Debt -998.5m / FCF TTM 602.5m)
Total Stockholder Equity = 4.18b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.71% (Net Income 491.9m / Total Assets 6.52b)
RoE = 11.76% (Net Income TTM 491.9m / Total Stockholder Equity 4.18b)
RoCE = 15.49% (EBIT 665.6m / Capital Employed (Equity 4.18b + L.T.Debt 112.3m))
RoIC = 11.46% (NOPAT 508.2m / Invested Capital 4.43b)
WACC = 8.80% (E(11.9b)/V(12.0b) * Re(8.77%) + D(146.5m)/V(12.0b) * Rd(14.58%) * (1-Tc(0.24)))
Discount Rate = 8.77% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -97.56 | Cagr: -2.53%
[DCF] Terminal Value 74.71% ; FCFF base≈588.2m ; Y1≈621.6m ; Y5≈729.4m
[DCF] Fair Price = 162.0 (EV 10.4b - Net Debt -998.5m = Equity 11.4b / Shares 70.5m; r=8.80% [WACC]; 5y FCF grow 6.33% → 2.50% )
EPS Correlation: 91.79 | EPS CAGR: 7.97% | SUE: 0.33 | # QB: 0
Revenue Correlation: 94.00 | Revenue CAGR: 2.34% | SUE: 0.57 | # QB: 0
EPS current Quarter (2027-03-31): EPS=2.71 | Chg30d=-0.70% | Revisions=-50% | Analysts=10
EPS current Year (2026-12-31): EPS=11.13 | Chg30d=-1.15% | Revisions=-79% | GrowthEPS=+5.9% | GrowthRev=+2.2%
EPS next Year (2027-12-31): EPS=12.29 | Chg30d=-1.29% | Revisions=-80% | GrowthEPS=+10.4% | GrowthRev=+2.9%
[Analyst] Revisions Ratio: -85% (up=1, down=29)